Compare SGU & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGU | KMDA |
|---|---|---|
| Founded | 1995 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.1M | 458.6M |
| IPO Year | 1995 | N/A |
| Metric | SGU | KMDA |
|---|---|---|
| Price | $12.52 | $8.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 27.5K | ★ 85.6K |
| Earning Date | 02-04-2026 | 03-04-2026 |
| Dividend Yield | ★ 5.85% | 2.40% |
| EPS Growth | ★ 102.23 | 30.41 |
| EPS | ★ 1.82 | 0.35 |
| Revenue | ★ $1,784,418,000.00 | $174,787,000.00 |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | N/A | $11.38 |
| P/E Ratio | ★ $6.94 | $23.70 |
| Revenue Growth | 1.04 | ★ 10.36 |
| 52 Week Low | $11.31 | $5.54 |
| 52 Week High | $13.75 | $9.16 |
| Indicator | SGU | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 59.29 |
| Support Level | $12.51 | $7.85 |
| Resistance Level | $12.90 | $8.88 |
| Average True Range (ATR) | 0.21 | 0.23 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 64.60 | 53.28 |
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.